Tumor-associated antigenic pattern in squamous cell carcinomas of the head and neck--analysed by SEREX

Bernd Heubeck1, Olaf Wendler, Klaus Bumm

  • 1Department of Otorhinolaryngology Head and Neck Surgery, University of Erlangen-Nuremberg, Waldstrasse 1, 91054 Erlangen, Germany. uwe.mueller-vogt@hno.immed.uni-erlangen.de

European Journal of Cancer (Oxford, England : 1990)
|July 14, 2006
PubMed

Insights

Researchers identified 17 immunogenic antigens in head and neck squamous cell carcinomas (HNSCC) using SEREX. KIAA0530

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Limited information exists on the antigenic profile of head and neck squamous cell carcinomas (HNSCC).
  • Tumor-associated antigens are crucial for developing immunotherapies.
  • Identifying novel antigens can lead to new therapeutic strategies.

Purpose of the Study:

  • To identify immunogenic antigens in head and neck squamous cell carcinomas (HNSCC).
  • To explore the potential of these antigens as targets for immunotherapy.

Main Methods:

  • Serological analysis of tumor antigens by recombinant cDNA expression cloning (SEREX) was employed.
  • A cDNA expression library from a pharynx HNSCC case was screened using autologous and heterologous sera.
  • Results were validated using RT-PCR and in situ hybridization.

Main Results:

  • 17 immunoreactive gene products (antigens) were identified from 37 positive clones.
  • KIAA0530 was confirmed to be associated with HNSCC immune response.
  • Heat shock transcription factor 2 (HSF2) antibodies were detected in HNSCC patients.

Conclusions:

  • The SEREX technique successfully identified 17 novel immunogenic antigens in HNSCC.
  • KIAA0530's clinical relevance in HNSCC was confirmed.
  • Further research is ongoing to evaluate these antigens for immunotherapy.

Related Concept Videos